Chou Yi-Hong, Liang Ja-Der, Wang Shen-Yung, Hsu Shih-Jer, Hu Jui-Ting, Yang Sien-Sing, Wang Hsin-Kai, Lee Tien-Ying, Tiu Chui-Mei
Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu, Taiwan.
Department of Radiology, Taipei Veterans General Hospital and School of Medicine, National Yang Ming University, Taipei, Taiwan.
J Med Ultrasound. 2019 Apr-Jun;27(2):81-85. doi: 10.4103/JMU.JMU_44_19. Epub 2019 Jun 24.
The purpose of this study was to report the safety of perfluorobutane (Sonazoid) as a vascular-phase imaging agent in characterizing focal liver lesions (FLLs).
From May 2014 to April 2015, a total of 54 individuals who received Sonazoid contrast-enhanced ultrasound (CEUS) were enrolled at 5 hospitals of 4 medical centers. All individuals were included in safety evaluation. A prospective study to evaluate the adverse effect (AE) incidences after intravenous administration of Sonazoid.
Sonazoid was well tolerated. Treatment-emergent adverse events (TEAEs) representing AE were recorded for 13 (24.1%) patients. The most common AE was abdominal pain (9.3%), followed by heart rate irregularity (5.6%). The majority of these patients (69.2%) experienced TEAEs that were mild in intensity. Sonazoid causes no significant AEs after intravenous injection. The only noteworthy AEs are related to tolerable myalgia (3.7%), abdominal pain (1.9%), and headache (1.9%). None of the 54 patients showed serious adverse effects.
Sonazoid shows good safety and tolerance of intravenous use during CEUS of the liver for evaluation of FLLs.
本研究旨在报告全氟丁烷(声诺维)作为血管期成像剂在肝脏局灶性病变(FLLs)特征性诊断中的安全性。
2014年5月至2015年4月,4个医疗中心的5家医院共纳入54例接受声诺维对比增强超声(CEUS)检查的患者。所有患者均纳入安全性评估。一项前瞻性研究,旨在评估静脉注射声诺维后的不良反应(AE)发生率。
声诺维耐受性良好。记录到13例(24.1%)患者出现代表AE的治疗中出现的不良事件(TEAE)。最常见的AE是腹痛(9.3%),其次是心律不齐(5.6%)。这些患者中的大多数(69.2%)经历的TEAE强度为轻度。静脉注射后声诺维未引起显著的AE。唯一值得注意的AE与可耐受的肌痛(3.7%)、腹痛(1.9%)和头痛(1.9%)有关。54例患者均未出现严重不良反应。
在肝脏CEUS检查中,声诺维在用于评估FLLs时显示出良好的静脉使用安全性和耐受性。